Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is a serious public health issue. Its evolution involves an acute stage, characterized by no specific symptoms, and the chronic stage during most individuals are asymptomatic, but about 30-40% of them become symptomatic presenting the cardiac or digestive disease. Host immune response mechanisms involved in symptomatic or asymptomatic chronic disease are not fully understood. The proinflammatory cytokines are crucial in host resistance. However, a fine control of this inflammatory process, by action of anti-inflammatory cytokines, is necessary to avoid tissue injury. This control was found to be responsible for no clinical manifestations in asymptomatic individuals. Toll-like receptors (TLRs) are extremely important in defining the cytokine profile released in response to a micro-organism. We found that patients with the cardiac form predominantly released the pro-inflammatory cytokines: IFN-c, TNF-a and IL-17 with the involvement of both, TLR2 and TLR4. In contrast, patients with asymptomatic disease release predominantly the anti-inflammatory cytokines IL-10 and TGF-b, but also with TLR2 and TLR4 participation. The mechanisms by which stimulation of the same TLRs results in release of different pattern of cytokines, depending on the patients group that is being evaluated, are discussed.
Introduction
Chagas disease (CD), whose aetiological agent is the protozoan Trypanosoma cruzi (T. cruzi), is a neglected tropical disease, although it is a serious public health issue, even in non-endemic countries [1] [2] [3] . According to the Pan American Health Organization, about 6 to 8 million of people are infected in the Americas, and 12,000 die each year [4] . In addition, the number of reported cases has increased over the past years, especially in European countries such as Spain, Italy and Switzerland, where most of the Latin immigrants live [5] [6] [7] . The CDC (Centers for Disease Control and Prevention) estimates that more than 300,000 people are infected with T. cruzi in the USA, and most of them were infected in endemic countries. Despite the presence of the vector in the USA, rare cases of the disease contracted within the country have been documented [8] .
The evolution of the disease involves two phases with distinct clinical manifestations. The acute phase lasts from 2 to 4 months, and it is usually characterized by nonspecific symptoms, despite the presence of intense parasitemia. The lack of treatment and the immune system inefficiency to completely eliminate the parasite ensure its persistence and the infected individual progresses to the chronic phase of the disease [9] .
The clinical course of chronic disease is variable, and it ranges from asymptomatic to severe disease with cardiovascular and/or gastrointestinal involvements. Most infected individuals present the indeterminate or asymptomatic chronic disease characterized by positive serology and no clinical manifestations [10] .
However, about 30-40% of them develop symptomatic CD [11] [12] [13] . Cardiac disease is the most important clinical manifestation of chronic symptomatic CD due to its frequency and severity [14, 15] . Nevertheless, the digestive form mainly characterized by the development of megacolon and megaesophagus resulting from enteric neuronal damage by the parasite also has an important degree of severity [16] [17] [18] .
The immune response against T. cruzi is complex, and it involves many effectors and regulators components [19] [20] [21] . Cytokines such as IFN-c, produced during innate and specific immune response, are considered essential for the control of the intracellular replication of T. cruzi. Macrophages activated with this cytokine release TNF-a which induces a second activation signal in these cells, which greatly increase their production of trypanosomicide molecules such as NO [22] [23] [24] [25] . During innate immune response, the predominant source of IFN-c is NK cells stimulated by IL-12 produced by infected macrophages and/or dendritic cells [9, 26, 27] .
During the specific immune response, these cells instruct the CD4 response to a Th1 polarization [28] . Besides the release of IFN-y, this profile of CD4 induces plasma cells to produce opsonizing antibodies and it activates CD8 cells to destroy infected cells containing amastigotes of T. cruzi at the same time. Once activated, these cells are also an important alternative source of IFN-c [19, 29] .
Also referring to specific immune response, other studies have shown a significant involvement of Th17 cells in resistance to infection with T. cruzi. Therefore, the IL-17A, which is the main cytokine produced by this subpopulation, is extremely important for stimulation of pro-inflammatory cytokines release and neutrophils activation [30, 31] .
Although the cited mechanisms are considered crucial for host resistance, they can be closely related to pathogenesis of the disease at the same time. Therefore, it is suggested that a fine control must occur to avoid exacerbated responses that result in tissue damage. Failure in this control is associated with symptomatic forms of the disease, as these patients present a profile of predominant inflammatory response versus an anti-inflammatory response in individuals with the indeterminate form [9] .
The predominance of an anti-inflammatory profile in asymptomatic patients may be associated, among other factors, with their greater ability to produce suppressive cytokines such as IL-10. This cytokine can be produced by several cell types including monocytes/macrophages, Th2 and Treg. Its role must be balanced, to not cause an overall suppression of effector responses, so that it eliminates the parasite and controls these responses to avoid tissue damage at the same time [27, [32] [33] [34] [35] .
Among the main factors that determine the profile of cytokines, which are predominantly released in response to a micro-organism, are the Toll-like receptors (TLRs) [36] [37] [38] [39] . Several molecules of T. cruzi have been identified as PAMPs to TLRs. The main ones are the glicoinositolfosfolip ıdes (GIPLs) found in large amounts on the surface of trypanosomatids, including T. cruzi, which work to anchor glycoproteins and lipopolysaccharides. Some studies have shown that GPIs derived from trypomastigotes (tGPIs) are recognized by TLR2 [40] [41] [42] . Another member of the GPI family, which is purified from epimastigotes (eGPIs), induces activation of the NF-jB by binding to TLR4 [43] .
Several studies have assessed the importance of signals by TLRs on the induction of the susceptibility or resistance to infection with T. cruzi [37, 38] . Most studies used knockout mice to one or more of these receptors, and the results showed that TLR2, TLR4, TLR7 and TLR9 are involved in mechanisms of resistance to infection with T. cruzi. Additionally, studies have shown the importance of these receptors in modulating both the innate and adaptive immune response. They also showed that there is a degree of redundancy in the actions of various TLRs, which means that while each of the receptors has its individual involvement, the concomitant absence of various TLRs is what will actually determine the susceptibility to infection, as T. cruzi has several ligands for different TLRs [37] . However, studies assessing the role of TLRs in determining the different clinical manifestations of patients are scarce. Differences in the expression or activation of these receptors, especially TLR2 and TLR4, might be responsible for the predominant pro-inflammatory or anti-inflammatory cytokine profile presented by patients with symptomatic or indeterminate form, respectively. Therefore, the current study assessed the surface expression of TLR2 and TLR4 in monocytes and lymphocytes as well as the involvement of these receptors in the production of TNF-a, IFN-c, IL-17, IL-10 and TGF-b by patients with the cardiac, digestive and indeterminate form of Chagas disease.
Materials and methods
Patients. A number of 16, 13 and 15 patients, with digestive, cardiac and indeterminate form of Chagas disease, were evaluated respectively. Overall, the group of patients consisted of 23 males and 21 females who were recruited from the General Service of Infectious diseases of the Clinical Hospital -Botucatu Medical School. They were conducted to this service by the Hemocenter from the same hospital when, at the time of blood donation, they had presented at least one positive serological test (ELISA, IFA, IHA) for Chagas disease. When they began to be monitored, they underwent another three serological tests of different principles (ELISA/Chemiluminescence, IHA and IFA), and those who were positive for at least two of these tests were considered as chronic patients. Patients diagnosed with other concomitant infectious diseases presenting immunosuppression and pregnant women were excluded. Besides, 16 individuals who, at the time of blood donation, were considered negative for screening tests were evaluated as controls. This study was approved by the Ethics Committee of Botucatu Medical School (protocol 233.464) and was performed in accordance with the principles of the Declaration of Helsinki, 1964. Informed consent was obtained from all patients and controls.
Peripheral blood mononuclear cells (PBMCs) isolation. Mononuclear cells were obtained from peripheral blood by separation on Ficoll-Histopaque gradient (Sigma-Aldrich, St. Louis, MO, USA). The halo rich in lymphocytes and monocytes was removed and washed by centrifugation with the culture medium RPMI 1640 (Nutricell, Campinas, São Paulo, Brazil) at 400 g for 15 min. After that, the cells were resuspended in complete medium consisted of RPMI-1640 supplemented with 2 mM L-glutamine, 40 lg/ml gentamycin (SigmaAldrich, St. Louis, MO, USA) and 10% foetal bovine serum (Sigma-Aldrich). Identification, counting and viability of cells were assessed using Trypan Blue staining, and concentration was adjusted to 1 9 10 6 cells/ml. Cell surface expression of TLR2 and or TLR4. PBMCs suspensions (1 9 10 6 /ml) from patients and controls were distributed in tubes for cytometry analysis (Becton and Dickinson, Franklin Lakes, NJ, USA) and centrifuged for 5 min at 450 g. Afterwards, cells were incubated with anti-human CD3 monoclonal antibody conjugated with PE-DY647 (EXBIO, Vestec, Czech Republic), anti-human CD14 monoclonal antibody conjugated with PE-DY647 (EXBIO, Vestec, Czech Republic), anti-human TLR4 conjugated with FITC (Biolegend, San Diego, CA, EUA) and anti-human TLR2 conjugated with PE (Biolegend) for 15 min in the dark. After samples were centrifuged (450 g, 10 min), supernatants were discarded and cells were suspended in 300 ll of ISOTON II electrolyte solution (Becton and Dickinson). For each test, there was a control tube in which cells were incubated with isotype control antibodies conjugated with the same fluorochromes used in the test. Analysis and cell acquisition were performed by flow cytometry (FACSCalibur TM , Becton and Dickinson) using the Cell Quest software (Becton, Dickinson and Company). Concerning the gating strategies applied to distinguish cell populations analysed via flow cytometry, FSC-SSC profile was used to distinguish total lymphocytes and monocytes and this subtype of cells was gated according to light scatter profile and the expression of CD3 and CD14. Acquisition was standardized to 10,000 events per sample.
Stimulation of PBMCs. Peripheral blood mononuclear cells (1 9 10 6 cells/ml) in complete medium were plated in 24-well culture plates in the absence or presence of TLR agonists, according to the manufacturers' recommendations (Invivogen, San Diego, CA, USA). The following concentrations of agonists were used: 5 lg/ml peptidoglycan (PGN) from Staphylococcus aureus (TLR2 agonist) and 1 lg/ ml ultra-pure lipopolysaccharide (LPS) from Escherichia coli K12 (TLR4 agonist). PBMCs were incubated with the agonists at 37°C under 5% CO 2 for 24 h. After incubation, the supernatants were aspirated, aliquoted and stored at À80°C prior to analysis. + cells (Mean of fluorescence intensity and cells percentage), ANOVA test for independent samples followed by means which were compared by the Multiple Tukey-Kramer test was used. For cytokines production analysis, nonparametric t-test followed by medians which were compared by Kruskal-Wallis test was performed. The significance level for all analyses was set at 5%.
Results

Expression of TLR2 and TLR4 on monocytes and lymphocytes
The expression of TLR2 and TLR4 on the surface of lymphocytes and monocytes of control subjects, and patients with indeterminate, cardiac and digestive forms were assessed by measuring the percentage of CD3 + and CD14 + cells which were positive for these receptors as well as by the mean of intensity of fluorescence (MIF). We found that the three groups of patients presented higher percentages of CD3 cells expressing TLR2 in relation to control individuals. Among the three groups of patients, those with the digestive form tended to present higher percentages. No differences among the four groups were detected in relation to the percentage of CD14 cells that express this receptor (Fig. 1A) . Still, in relation to TLR2 expression, CD3 cells from the three groups of patients presented higher means of fluorescence intensity in relation to control groups, while those with cardiac form presented higher values in comparison with other two groups. The same profile of response was obtained when MIF referring TLR2 expression was analysed in CD14 cells (Fig. 1B, C) . Regarding TLR4, patients of the three groups presented higher percentages of CD3 cells expressing this receptor when compared to controls, although there were no differences among them. Contrary results were detected in relation to CD14 cells percentage, as lower values were found in patient groups and mainly in those with the indeterminate form (Fig. 1A) .
Analysis of MIF referring to TLR4 expression by CD3 and CD14 cells did not show significant differences among the groups (Fig. 1B, C) . Overall, considering the two evaluations (percentages of cells and MIF), we can consider that patients with the cardiac and digestive form tend to express higher levels of TLR2 in relation to those with the indeterminate form. Patients with the digestive form tend to express higher levels of TLR4 in relation to other patients.
Participation of TLR2 and TLR4 in cytokine production
After analysing TLR2 and TLR4 expression in the three groups of patients and control subjects, we assessed their participation in cytokines production. For this, IFN-c, TNF-a, IL-17, IL-10 and TGF-b production were evaluated after PBMCs stimulation with PGN and/or LPS, agonists of TLR2 and TLR4, respectively (Fig. 2) . PBMCs from patients with the cardiac form produced significantly higher levels of IFN-c when compared to other groups ( Fig. 2A) . It is important to consider that this higher production occurs after cells stimulation with PGN and/or LPS which means that both TLR2 and TLR4 are involved in this cytokine production. Similar results were obtained in relation to IL-17 production (Fig. 2B) . Patients with the cardiac form also produce higher levels of TNF-a when compared to other groups. However, this result was obtained only after stimulation with PGN (Fig. 2C) .
However, different results were found regarding IL-10 ( Fig. 2D ) and TGF-b (Fig. 2E ) production, as higher production of these cytokines was detected in patients with the indeterminate form, after cell stimulation with both agonists. Overall, we detected that, except for TNF-a, both TLR2 and TLR4 are involved in the production of all the cytokines evaluated. Nevertheless, stimulation of these receptors in patients with the cardiac form leads to higher production of pro-inflammatory cytokines such as IFN-c, IL-17 and TNF-a, while the stimulation of the same receptors in patients with the indeterminate form results in higher production of anti-inflammatory cytokines such as IL-10 and TGF-b. No relevant differences were detected in the results presented by patients with the digestive form if compared to the other groups.
Discussion
In this study, we hypothesized that differences in cytokines profile presented by cells of symptomatic and + and CD14 + cells expressing TLR2 and TLR4 in patients with indeterminate, cardiac and digestive forms of Chagas disease and control subjects. Gating strategy was used to distinguish cell populations analysed by flow cytometry. FSC-SSC profiles were used to distinguish monocytes and total lymphocytes. The results are represented by AE standard deviation. *P < 0.05 control subjects 9 indeterminate, cardiac and digestive patients.
• P < 0.05 digestive patients 9 cardiac patients.
# P < 0.05 indeterminate patients 9 control subjects. Expression of TLR2 and TLR4 evaluated by mean of fluorescence intensity (MIF) (B) was assessed in CD3 + and CD14 + cells from patients with indeterminate, cardiac and digestive forms of Chagas disease and control subjects. The results are represented by AE standard deviation. *P < 0.05 control subjects 9 indeterminate, cardiac and digestive patients.
•P < 0.05 cardiac 9 digestive patients. # P < 0.05 cardiac 9 indeterminate, digestive and control subjects. Representative histograms of TLR2 and TLR4 expression (C) relative to TLR2 and TLR4 expression by CD3 + and CD14 + cells from control subjects (CTL -blue line), patients with digestive (PD -green line), cardiac (PC -red line) and indeterminate (PI -purple line) forms of Chagas disease, evaluated by mean of fluorescence intensity (MIF). ............................................................................................................................................................... asymptomatic chagasic patients might be associated with differences on expression and/or in signals provided by TLR2 and/or TLR4 that are the main TLRs involved in the recognition of T. cruzi PAMPs. The experimental approach was to assess in each group, whether there is a differential expression of these receptors as well as to analyse the profile of cytokines produced by mononuclear cells stimulated with agonists of these receptors.
We found that patients with cardiac form predominantly release IFN-c, TNF-a and IL-17 in contrast with those with indeterminate form that produce IL-10 and TGF-b. These findings corroborate recent studies showing that cardiac Chagas patients exhibit a strong inflammatory response expressed by higher levels of TNF-a, IFN-c and IL-6 when compared to those with indeterminate form that released greater IL-10 levels [44] . Accordingly, other studies have shown a predominance of Th1-type T cells in myocardium infiltrate and in peripheral blood cells of patients with cardiac form [45, 46] as a consequence of the chemokines profile released at infected site [47] [48] [49] . The inflammatory infiltrate composed of these cells in the myocardium is responsible for high IFN-c production which are detected on the periphery [46, 50] .
In addition to Th1 cells, a high number of CD8 cells producing TNF-a and IFN-c [51, 52] , but a reduced number of Tregs cells secreting IL-10 was found. In contrast, in patients with indeterminate form high IL-10 levels associate with greater percentage of CD4 + CD25
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+ cells was detected [53] . Besides Tregs, monocytes of indeterminate patients produce higher levels of IL-10 than the cardiac patients [32] . Based on these results, although we have not identified the populations of mononuclear cells that release the cytokines tested in the supernatants, we can suggest that Th1 and CD8 cells are preferentially induced in cardiac patients, which result in higher production of IFN-c and TNF-a. On the contrary, in indeterminate patients, monocytes and Tregs are induced to release higher IL-10 and TGF-b levels.
Regarding the IL-17, our results suggest its participation on the mechanisms inducing myocarditis, as high levels were detected in patients with cardiac disease. At first, this interpretation is quite consistent, as IL-17 is traditionally regarded as potent pro-inflammatory cytokine. However, it is not in agreement with the latest studies showing that this cytokine has an essential role in controlling inflammatory response in myocardium. Mice infected with T. cruzi and treated with anti-IL17A monoclonal antibody, presented an increase in myocarditis and mortality [54] . Other studies have shown that high IL-17 production is associated with better cardiac function [31, 55] . Regulation of the inflammatory infiltrate by IL-17 involves the inhibition of Th1 cells differentiation, production of cytokines and chemokines and the influx of inflammatory cells into the cardiac tissue. Additionally, regulation by IL-17 has been associated with activation of neutrophils producing IL-10 [56] . Despite these studies, we can consider that in cardiac patients analysed in this study, the preponderant role of IL-17 was proinflammatory.
In this study, the analysis of the involvement of TLR2 and TLR4 in the differences in cytokines profiles presented by symptomatic and asymptomatic patients showed that both receptors are involved in the production of all the cytokines analysed. However, stimulation of these two receptors in symptomatic patients, particularly those with the cardiac form, leads to preferential production of proinflammatory cytokines in contrast to anti-inflammatory ones in indeterminate patients. Thus, stimulation of the same receptor in different individuals may lead to the production of pro-inflammatory or anti-inflammatory cytokines.
The involvement of these receptors in the production of pro and anti-inflammatory cytokines is supported by previous studies which show that different GPIs derived from the T. cruzi are recognized by TLR2 or TLR4 and that the signals provided by both have an important role in either susceptibility or resistance of the host to infection [37, 38, [40] [41] [42] [43] . Thus, the stimulation of the same receptor may lead to either production of pro-or anti-inflammatory cytokines, depending on the individual.
In an attempt to establish an association between cytokine production and TLR2 and TLR4 expression by patients' cells, we can suggest that one of the explanations for the predominant inflammatory response profile in patients with cardiac disease in relation to the digestive might be that the former tended to demonstrate a greater expression of TLR2 receptor in both CD3 + cells and in CD14 + cells. This did not occur with digestive patients whose highest levels were only detected in CD3 + cells. The participation of TLR2 in the development of cardiac disease has been highlighted. Studies have shown the fundamental role of this receptor in signalling for the production of IL1-b which is considered an important mediator of cardiomyocytes hypertrophy in mice infected with T. cruzi [57] .
However, the above explanation is not consistent when we analysed the production of IL-10 and TGF-b. As the two receptors are also involved in the production of these cytokines, patients with the cardiac form should also produce high levels of them, which did not occur.
High polymorphism of TLRs and their adapter molecules are reported in the literature. This process may explain different responses among individuals after activation of the same receptor. This can be one possible explanation for our results. A study that evaluated 169 patients with chronic Chagas' disease and 76 asymptomatic individuals found that T. cruzi-infected individuals who are heterozygous for the MAL/TIRAP S180L variant, which leads to a decrease in signal transduction upon the link of TLR2 or TLR4 with their respective ligands, may have a lower risk of developing chronic Chagas cardiomyopathy [58] .
Thus, studies aiming to analyse this polymorphism in patients and its consequences for the development of the different manifestations of the disease should be encouraged. At first, we consider that in addition to patients with cardiac disease, those with the digestive form might also present important differences in relation to asymptomatic individuals. However, these differences were clear only in individuals with cardiac involvement. We believe that further analysis of the clinical conditions of each patient and his/her cytokines response are needed to confirm these results.
Conclusion
Our results contribute to a better understanding of immune response mechanisms provided by the host infected with T. cruzi, focusing on those involved in the different clinical manifestations of the disease, which are a major challenge for researchers that target future interferences in these patients, to prevent the development of symptomatic chronic Chagas disease at the end.
